A 58-year-old man with a 15-year history of alcohol use disorder presents to the emergency department with hematemesis and melena. On examination, he is tachycardic (HR 110/min), hypotensive (BP 88/54 mmHg), and has clinical signs of cirrhosis including jaundice, spider angiomata, and ascites. Upper endoscopy reveals large esophageal varices with active bleeding. After two units of packed RBCs and fresh frozen plasma, his bleeding is controlled endoscopically with band ligation. Which of the following is the most appropriate next step in the management of this patient to prevent variceal rebleeding?

Explanation

## Management of Variceal Rebleeding Prevention **Key Point:** After successful acute variceal hemorrhage control, beta-blockers (propranolol, carvedilol, or nadolol) are the gold standard for secondary prophylaxis to reduce the risk of rebleeding and mortality. ### Mechanism of Beta-Blocker Efficacy Beta-blockers reduce portal pressure by: 1. Decreasing cardiac output (β₁ effect) 2. Reducing splanchnic vasodilation (β₂ effect on mesenteric vessels) 3. Net result: 20–25% reduction in portal pressure gradient (goal: reduce HVPG by ≥20% or to <12 mmHg) **High-Yield:** The target is a 25% reduction in resting heart rate (or absolute reduction to 55 bpm), which correlates with adequate portal pressure reduction. ### Comparison of Secondary Prophylaxis Strategies | Strategy | Indication | Efficacy | Duration | |----------|-----------|----------|----------| | **Beta-blockers (propranolol/carvedilol)** | First-line for all variceal bleeders | Reduces rebleeding by 40–50% | Indefinite or until liver transplant | | **Repeat EVL (endoscopic variceal ligation)** | Adjunct; variceal eradication goal | Reduces rebleeding vs. sclerotherapy | Every 2–4 weeks until variceal eradication | | **Octreotide** | Acute bleeding control only | No role in chronic prophylaxis | Acute phase only (2–5 days) | | **TIPS** | Refractory bleeding, portal hypertensive gastropathy, or failure of beta-blockers + EVL | Effective but high encephalopathy risk | Reserved for rescue therapy | **Clinical Pearl:** Combination therapy (beta-blockers + repeat EVL) is superior to either modality alone for secondary prophylaxis. EVL should be repeated every 2–4 weeks until variceal eradication is achieved, then continued on beta-blockers. ### Why Propranolol 40 mg BD Is Correct Here 1. **Acute bleeding controlled** → transition to chronic prophylaxis 2. **Beta-blocker is first-line** → reduces rebleeding by 40–50% and improves survival 3. **Dose titration goal:** achieve 25% reduction in baseline HR or absolute HR of 55 bpm 4. **Indefinite duration** required in cirrhotic patients with varices **Warning:** Do not confuse acute bleeding management (octreotide + EVL) with secondary prophylaxis (beta-blockers + EVL). ```mermaid flowchart TD A[Acute Variceal Hemorrhage]:::outcome --> B[Stabilize + IV fluids]:::action B --> C[Octreotide 50 mcg/hr IV]:::action C --> D[Upper endoscopy]:::action D --> E[Endoscopic variceal ligation]:::action E --> F{Bleeding controlled?}:::decision F -->|Yes| G[Transition to secondary prophylaxis]:::action F -->|No| H[Repeat EVL or TIPS]:::action G --> I[Beta-blocker: propranolol/carvedilol]:::action I --> J[Target: 25% HR reduction]:::action J --> K[Repeat EVL every 2-4 weeks]:::action K --> L[Variceal eradication achieved]:::outcome ``` [cite:Harrison 21e Ch 297]